Abbott eyes lung cancer diagnostics
This article was originally published in The Gray Sheet
Executive Summary
German biotech firm BioVision will receive research payments and possible milestone and royalty compensation under a new biomarker development agreement with Abbott. Promising peptide- and protein-based markers for lung cancer identified by BioVision could make their way onto Abbott platforms...